Influence of Uremia and Hemodialysis on the Turnover and Metabolic Effects of Glucagon

ROBERT S. SHERWIN, CHRISTINE BASTL, FREDRIC O. FINKELSTEIN, MERRICK FISHER, HENRY BLACK, ROSA HENDLER, and PHILIP FELIG

From the Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

ABSTRACT To evaluate the mechanism and role of hyperglucagonemia in the carbohydrate intolerance of uremia, 19 patients with chronic renal failure (12 of whom had undergone chronic hemodialysis for at least 11 mo) and 35 healthy control subjects were studied. Plasma glucagon, glucose, and insulin were measured in the basal state, after glucose ingestion (100 g), after intravenous alanine (0.15 g/kg), and during a 3-h continuous infusion of glucagon (3 ng/kg per min) which in normal subjects, raised plasma glucagon levels into the upper physiological range.

Basal concentrations of plasma glucagon, the increment in glucagon after infusion of alanine, and post-glucose glucagon levels were three- to fourfold greater in uremic patients than in controls. The plasma glucagon increments after the infusion of exogenous glucagon were also two- to threefold greater in the uremics. The metabolic clearance rate (MCR) of glucagon in uremics was reduced by 58% as compared to controls. In contrast, the basal systemic delivery rate (BSDR) of glucagon in uremics was not significantly different from controls.

Comparison of dialyzed and undialyzed uremics showed no differences with respect to plasma concentrations, MCR, or BSDR of glucagon. However, during the infusion of glucagon, the increments in plasma glucose in undialyzed uremics were three- to fourfold greater than in dialyzed uremics or controls. When the glucagon infusion rate was increased in controls to 6 ng/kg per min to produce increments in plasma glucagon comparable to uremics, the glycemic response remained approximately twofold greater in the undialyzed uremics. The plasma glucose response to glucagon in the uremics showed a direct linear correlation with oral glucose tolerance which was also improved with dialysis. The glucagon infusion resulted in a 24% reduction in plasma alanine in uremics but had no effect on alanine levels in controls.

It is concluded that (a) hyperglucagonemia in uremia is primarily a result of decreased catabolism rather than hypersecretion of this hormone; (b) sensitivity to the hyperglycemic effect of physiological increments in glucagon is increased in undialyzed uremic patients; and (c) dialysis normalizes the glycemic response to glucagon, possibly accounting thereby for improved glucose tolerance despite persistent hyperglucagonemia. These findings thus provide evidence of decreased hormonal catabolism contributing to a hyperglucagonemic state, and of altered tissue sensitivity contributing to the pathophysiological action of this hormone.

INTRODUCTION

Chronic renal failure is characterized by an increased incidence of glucose intolerance (1–3). The role of insulin resistance in the pathogenesis of the carbohydrate intolerance in uremia has recently been emphasized (4). Decreased sensitivity to the hypoglycemic effects of endogenous (2, 5, 6) and exogenous (3, 5–8) insulin has been observed in uremic man, whereas basal and glucose-stimulated insulin concentrations are normal or increased (1–3, 5, 6, 9). After chronic dialysis, glucose tolerance generally improves in association with increased tissue sensitivity to insulin (5, 9–13). The mechanism of uremia-induced insulin resistance and the improvement in insulin sensitivity after dialysis has not been established. Recently, Bilbrey et al. (14) observed increased levels of circulating glucagon, a known insulin antagonist, in chronic renal failure. The pathophysiological significance of these findings was questioned however, since dialysis resulted in marked im-
Improvement in glucose tolerance despite unchanged levels of plasma glucagon (14). The possible role of altered tissue responsiveness to physiological increments of glucagon in uremia and the effect of dialysis on glucagon sensitivity have not been previously examined. Furthermore, whether hyperglucagonemia in uremia is a consequence of increased secretion or is solely due to reduced hormone catabolism has not been determined.

The present study was consequently undertaken to examine the turnover of plasma glucagon and the tissue responsiveness to physiological increments in glucagon in uremia. In the evaluation of glucagon kinetics and sensitivity, special attention was given to the influence of dialysis on these parameters. The data indicate that hyperglucagonemia in uremia is a result of decreased turnover rather than hypersecretion. Furthermore, uremia is associated with increased sensitivity to the hyperglycemic effects of glucagon. This increased tissue sensitivity to glucagon returns to normal after chronic dialysis.

METHODS

Subjects

Two groups of subjects were studied. The control group consisted of 35 healthy, nonobese volunteers (18 males and 17 females) within 15% of ideal body weight (based on 1959 Metropolitan Life Insurance Company tables). The subjects ranged in age from 18 to 50 yr. They consumed weight-maintaining diets containing at least 200 g of carbohydrate and were taking no drugs. All had negative primary family histories for diabetes mellitus and none had an elevated fasting plasma glucose. 20 of the subjects received an oral glucose tolerance test (100 g) and all demonstrated a normal response.

The uremic group consisted of 19 ambulatory patients (12 males and 7 females) with chronic renal failure, aged 20-63 yr (44±4 yr, mean±SE). Seven of the patients had not undergone treatment with dialysis before study (undialyzed group). 12 patients had undergone chronic hemodialysis for at least 11 mo in the dialysis unit of the Yale-New Haven Hospital before study. None of the uremic patients had evidence of an acute medical illness or peripheral edema at the time of study. None were receiving corticosteroids. The medications received by dialyzed and undialyzed groups were similar with the exception that 9 of 12 dialyzed subjects and 2 of 7 undialyzed subjects received parenteral androgens. All but three uremic subjects were within 15% of ideal body weight (based on 1959 Metropolitan Life Insurance Company tables). The patients consumed weight-maintaining diets containing at least 250 g of carbohydrate for 3 days before study. Dialyzed patients consumed approximately 80 g of protein, while undialyzed patients were restricted to 50-60 g of protein. Pertinent laboratory data in the uremic group included: serum creatinine, which ranged from 7.5 to 25.1 mg/100 ml (15.6±1.2, mean±SE); serum potassium, 4.0-6.9 meq/liter (5.3±0.2, mean±SE); serum bicarbonate, 11.5-25.0 meq/liter (18.6 ±1.0, mean±SE); serum calcium, 6.3-10.4 mg/100 ml (8.6 ±0.2, mean±SE); and serum phosphate 3.2-14.4 mg/100 ml (6.5±0.6, mean±SE). There were no significant differences with respect to these laboratory values, ages, or weights between the dialyzed and undialyzed patients.

Procedures

All subjects were studied in the postabsorptive state after a 12-15-h overnight fast. Uremic subjects were instructed to omit all medications on the day of study. Dialysis patients were studied just before their next dialysis. An indwelling catheter was inserted in an antecubital vein for blood sampling. An additional catheter was inserted in the contralateral vein or ateriovenous fistula during the glucagon-infusion studies. Subjects were recumbent for at least 20-30 min before study. At least two control blood samples were obtained at 10-15-min intervals before glucose, alanine, or glucagon administration. Control values presented in each study represent the mean of the base-line determinations. Three types of procedures were employed.

Oral glucose tolerance. A 100-g oral glucose tolerance test was performed in 20 normal and 10 uremic subjects. In this study, blood samples were drawn at 30-60-min intervals for 3 h after ingestion of 100 g glucose dissolved in 200 ml of water.

Alanine infusion. L-Alanine (Nutritional Biochemical Corp., Cleveland, Ohio) was given intravenously (0.15 g/kg body weight) over 2-4 min to 21 normal and 9 uremic subjects. Methods used in the preparation of the alanine infusate have previously been described (16). Blood samples were obtained at 10-30-min intervals for 90 min after the infusion of alanine.

Glucagon infusion. Crystalline beef and pork glucagon (Eli Lilly and Co., Indianapolis, Ind.) was administered as a continuous infusion via a peristaltic pump (Extracorporeal Medical Specialties, Inc., King of Prussia, Pa.) to 21 normal and 10 uremic subjects. Before administration, the glucagon was initially diluted in sterile, pyrogen-free water containing 300 mg/100 ml of human serum albumin (Armour Pharmaceutical Co., Chicago, Ill.). This solution was further diluted with physiological saline and an aliquot of the subject's whole blood (4 ml of whole blood per 100 ml of infusate, to prevent adherence of the glucagon to glassware or tubing) so as to achieve a final glucagon concentration in the infusate of 500 ng/ml. The continuous infusion dose was 3 ng/kg body weight per min, administered for 150-180 min. In eight additional healthy controls, glucagon was infused at a dose of 6 ng/kg body weight per min. Blood samples were obtained at 15-30 min intervals during the infusion.

Analyses and calculations

Glucose was measured by the glucose oxidase technique (17). The methods employed for the determination of plasma immunoreactive insulin, plasma immunoreactive glucagon (using Unger antibody 30K), and plasma acidic and neutral amino acids have been described previously (18).

The metabolic clearance rate of glucagon (MCRg), the volume of plasma completely and irreversibly cleared of glucagon per minute, was calculated according to the formula (19):

$$MCR_g = \frac{\text{Glucagon infused per minute}}{\text{Glucagon concentration at equilibrium} - \text{basal concentration}}$$

Abbreviations used in this paper: BSDRG, basal systemic delivery rate of glucagon; MCRg, metabolic clearance rate of glucagon.

Influence of Uremia and Hemodialysis on Glucagon 723
RESULTS

Glucagon concentrations in the basal state and after glucose and alanine administration. In accordance with the observations of Bilbrey et al. (14), the postabsorptive glucagon concentration was increased fourfold in uremic patients (349±32 pg/ml) as compared to controls (90±8 pg/ml, \( P < 0.001 \)). Basal glucagon levels in uremias were not significantly different in dialyzed (326±34 pg/ml) or undialyzed patients (384±65 pg/ml). Hyperglucagonemia was also observed in the uremic group after glucose (Fig. 1) or alanine administration (Fig. 2). After glucose ingestion, glucagon concentration in the uremics fell by 20–25% below postabsorptive levels; however, the postglucose values in the uremics remained three- to fourfold greater than in the controls (Fig. 1). After intravenous alanine, plasma glucagon concentration increased in both normal and uremic subjects (Fig. 2). The mean maximal glucagon increment (401±135 pg/ml) and the area under the glucagon-response curve (15,880±4,875 pg/ml x min) were three- to fourfold greater than in the controls (106±13 pg/ml \( P < 0.05 \)), and 4,561±639 pg/ml x min \( P < 0.05 \), respectively). More striking, however, was the persistence of the glucagon response in the uremics. Glucagon increments 50 min after alanine were markedly increased in the uremics (221±66 pg/ml vs.

![Figure 1](image1.png)

**FIGURE 1** Plasma glucagon levels in the basal state and after the oral administration of 100 g of glucose to normal and uremic subjects. \( P \) values refer to the significance of the changes from the basal state (0 time) within each group. Despite the fall in plasma glucagon induced by glucose in the uremic group, glucagon concentrations remained significantly higher in the uremic group than in controls throughout the period of study \( (P < 0.001) \). No differences were noted with respect to dialyzed vs. nondialyzed uremics; the data for both uremic groups are consequently combined in the figure.

In this calculation it was assumed that: (a) endogenous glucagon secretion remains at basal levels throughout each study; (b) exogenous beef and pork glucagon turnover is indistinguishable from that of endogenous origin; and (c) glucagon removal is linear over the range of concentrations studied. Recent studies from our laboratory in normal man have, in fact, shown that glucagon removal is linear over a wide range of physiological concentrations (including levels similar to those observed in uremia). In addition, ingestion of glucose during a continuous infusion of exogenous glucagon results in a significant decline in plasma glucagon concentration (as compared to subjects receiving glucagon alone), thus suggesting continued basal secretion of endogenous glucagon during the infusion of exogenous hormone (20). The basal systemic delivery rate of glucagon (BSDR\(_b\)), the quantity of endogenous glucagon released into the systemic circulation each minute, is calculated as the product of the basal plasma glucagon concentration and MCR\(_b\) (19). The term BSDR\(_b\) was chosen since our calculations exclude that portion of total splanchnic glucagon secretion removed by the liver before entering the general circulation.

Statistical analyses were performed with the Student's \( t \) test (the paired \( t \) test was used when applicable), linear regression analysis, and analysis of variance (21). Data in the text are presented as the mean±SE.


![Figure 2](image2.png)

**FIGURE 2** Changes in plasma glucagon after the infusion of alanine (0.15 g/kg) in normal and uremic subjects. Glucagon levels were significantly greater in the uremic group at 50 min \( (P < 0.02) \) and at 60 min \( (P < 0.05) \). No differences were noted with respect to dialyzed vs. nondialyzed uremics; the data for both uremic groups are consequently combined in the figure.

724  **Sherwin, Bastl, Finkelstein, Fisher, Black, Hendler, and Felig**
40±7 pg/ml in controls, P < 0.02). The prolonged elevation of plasma glucagon is compatible with decreased hormone turnover in uremia. The plasma glucagon responses to glucose and alanine administration were not significantly different in the dialyzed as compared to the undialyzed patients.

**Glucagon kinetics in uremic and normal subjects.**

The continuous infusion of glucagon in the control and uremic patients resulted in stable plasma glucagon concentrations after 15-45 min (Fig. 3). However, the increment in glucagon in the uremic group (581±48 pg) was two- to threefold greater than in controls (233 ±13 pg/ml, P < 0.001). Furthermore, the time required to reach a stable plateau after glucagon administration was longer in the uremics (45 min) than in controls (15 min), thus suggesting decreased hormone degradation. The calculated MCRs was 5.8±0.6 ml/kg per min in the uremics, which is 58% below that observed in controls (13.8±0.9 ml/kg per min P < 0.001). In contrast, the BSDRs was not significantly different in uremic patients (1.78±0.20 ng/kg per min) as compared to healthy controls (1.34±0.17 ng/kg per min, P > 0.1). Chronic dialysis had no effect on the increment in plasma glucagon induced by the glucagon infusion (569±41 pg/ml in the dialyzed group and 593 ±93 in the undialyzed group), nor did it affect the calculated MCRs (5.9±0.4 ml/kg per min in dialyzed uremics and 5.8±1.3 in undialyzed uremics). Similarly, BSDRs was not significantly different in dialyzed (2.03 ±0.34 ng/kg per min) and undialyzed uremics (1.53 ±0.21 ng/kg per min, P > 0.1).

**Glucose and insulin concentrations in the basal state and in response to glucose ingestion.** The postabsorptive glucose concentration was increased in the uremic patients (93±4 mg/100 ml) as compared to controls (78±1 mg/100 ml, P < 0.001). Basal glucose concentration was not significantly different in dialyzed (89 ±4 mg/100 ml) and undialyzed (96±5 mg/100 ml) uremics. Similarly, postabsorptive insulin concentration was increased in uremic patients (24±3 vs. 14±1 μU/ml in controls, P < 0.005). However, when uremic patients were subdivided into undialyzed (30±6 μU/ml) and dialyzed (19±3 μU/ml) subjects, only the undialyzed uremics demonstrated significant basal hyperinsulinemia (P < 0.02).

After oral glucose administration, the plasma glucose concentration was significantly increased in the uremic group as compared to healthy controls (Fig. 4A). When uremics were subdivided on the basis of dialysis, undialyzed uremics demonstrated significantly increased glucose values when compared to dialyzed uremics (Fig. 4B). The improved glucose tolerance in the dialyzed group is also indicated by the fact that the glucose values in this group differed significantly from the control subjects only at 120 and 180 min (P < 0.05) (Fig. 4B). Plasma insulin concentrations after glucose ingestion closely paralleled the glucose response. Uremic patients demonstrated significantly increased insulin levels when compared to controls (Fig. 4C). However, whereas the glucose-stimulated insulin response was 2- to 10-fold above control levels in the undialyzed uremic group throughout the 3-h study, the dialyzed uremics showed only a delayed, 2- to 3-fold increment in insulin (Fig. 4D).

**Glucose and insulin responses to intravenous glucose.**

After alanine administration, the mean maximal increments in glucose and insulin for the uremic group as a whole (7±2 mg/100 and 27±7 μU/ml, respectively), were not significantly different from normal subjects (6±1 mg/100 ml and 15±2 μU/ml, respectively). However, when uremics were subdivided according to dialysis, the mean maximal increments in glucose in the undialyzed uremics (12±3 mg/100 ml) tended to be greater than in controls (6±1 mg/100 ml, P < 0.1) or in dialyzed uremics (3±1 mg/100 ml, P < 0.05). Similarly, the mean maximal increment in insulin in the undialyzed uremics (43±12 μU/ml) was significantly greater than in controls (15±2 μU/ml, P < 0.05) or in dialyzed uremics (11±2 μU/ml, P < 0.05).

*Influence of Uremia and Hemodialysis on Glucagon*
Glucose and insulin response to glucagon administration. The increment in plasma glucose concentration after intravenous glucagon infusion was two- to fourfold greater in the uremics as a whole, as compared to controls (Fig. 5A). However, when the effect of dialysis on glucagon-induced hyperglycemia was examined, the undialyzed uremics accounted for the differences observed. Despite comparable increments in plasma glucose in the dialyzed and undialyzed subjects (see above), the glucose response to glucagon was increased above control levels only in the undialyzed uremics (Fig. 5B). The mean maximal glucose increment in undialyzed uremics (37±9 mg/100 ml) was three- to fourfold greater than in dialyzed uremics (10±1 mg/100 ml, P < 0.02) or controls (10±1 mg/100 ml, P < 0.02). Furthermore, the area under the glucose-response curve in the undialyzed uremics (2,922±882 mg/100 ml × min) was significantly when compared to dialyzed uremics (730±215 mg/100 ml × min, P < 0.05) or controls (577±150 mg/100 ml × min, P < 0.02). For the entire uremic group, a significant linear correlation was observed between the maximal glucose response to glucagon administration and the 2-h plasma glucose concentration during the oral glucose tolerance test (r = 0.82, P < 0.05).

Changes in plasma insulin after glucagon administration were similar to those demonstrated for glucose. Increases in the plasma insulin response to glucagon in uremic subjects were accounted for by hyperinsulinemia in the undialyzed group only (Fig. 5C and D). Mean maximal insulin increments in undialyzed uremics (27 ±6 µU/ml) exceeded those of controls (9±1 µU/ml, P < 0.01) and dialyzed uremics (5±1 µU/ml, P < 0.01).

In addition to the 3 ng/kg per min infusion of glucagon, the healthy control subjects received infusions
at a rate of 6 ng/kg per min. This rate of infusion resulted in increments in plasma glucagon in the normal group which were equivalent to those observed in uremics during the 3 ng/kg per min infusion (Fig. 6). Despite comparable hyperglucagonemia, the glucose rise in the undialyzed uremics exceeded that of healthy controls (Fig. 6). The mean maximal glucose increment in the control subjects receiving the 6 ng/kg per min glucagon infusion (16±3 mg/100 ml) was less than half that observed in the undialyzed uremic group receiving the 3 ng/kg per min infusion (37±9 mg/100 ml, P < 0.05). The maximal insulin increment in the controls during the 6 mg/kg per min infusion (12±3 μU/ml) was significantly below that observed in the undialyzed uremics during the 3 ng/kg per min infusion (27±6, P < 0.05).

Plasma amino acids in the basal state and after glucagon administration. Plasma amino acid concentrations in the basal state and the changes observed after glucagon infusion are shown in Table 1. Uremic subjects demonstrated threefold increases in basal levels of citrulline and cystine (P < 0.001), as well as elevated taurine (P < 0.05), glycine (P < 0.01), and proline (P < 0.001) concentrations. Basal valine (P < 0.005), tyrosine (P < 0.02), and α-aminobutyrate (P < 0.05) concentrations were significantly reduced. No differences were observed between dialyzed and undialyzed subjects except in the case of glycine. Glycine concentration in the dialyzed group (548±90 μmol/liter) was twice that observed in the undialyzed group (249±18, P < 0.01) or in normal controls (207±16, P < 0.005).

The glucagon infusion (3 ng/kg per min) failed to produce any consistent changes in plasma amino acid concentrations in the normal control group, except for a 7% decline in serine (Table 1). In contrast, a significant fall in virtually all amino acids was demonstrable in the uremic group (Table 1). The magnitude of the decrease in alanine (24±2%) exceeded that of all other amino acids. The amino acid response to glucagon was the same in dialyzed and undialyzed uremic patients. When the glucagon infusion rate was increased to 6 mg/kg per min in normals to achieve increments in plasma glucagon comparable to the uremics (Fig. 6), plasma alanine concentration still failed to decline in the normal group (Fig. 7). With the exception of small (10–19%) reductions in glycine, serine, and threonine, the other amino acids were also unchanged by the high-dose glucagon infusion.

DISCUSSION

The current data demonstrate that chronic renal failure is associated with hyperglucagonemia in the basal state, after glucose suppression, and after alanine stimulation. Similar results have been previously reported with respect to basal and postglucose values (14). Bilbrey et al., however, failed to observe augmented glucagon levels after protein ingestion (14). Whether the differences observed between protein ingestion and intravenous alanine are related to altered protein absorption in uremia (22), or are due to the different nature of the aminogenic stimulus remains to be determined. The present findings extend previous observations, (a) by providing data on the relative contributions of altered hormone catabolism and secretion to increased plasma glucagon levels in uremia, and (b) by evaluating the effects of uremia and dialysis on the glycemic and amino acid responses to physiological increments in plasma glucagon.

In the uremic group, the MCRa was decreased by 58% as compared to healthy subjects. In contrast, the BSDRs was unchanged from controls. These data thus suggest that hyperglucagonemia in uremia is a consequence of decreased hormonal catabolism rather than hypersecretion. The techniques employed in the current study cannot exclude the possibility of increased hepatic extraction of glucagon and associated hypersecretion in the uremic group. However, previous observations in intact man have demonstrated a portal-peripheral gradient for glucagon which is no greater than 1:3:1, indicating that the liver is a minor site of glucagon degradation (23). Thus, the comparable BSDRs in the uremic and normal subjects are likely to be a close approximation of the true pancreatic secretory rates.

It should be noted that the calculations employed in determining MCRa assume ongoing secretion of en-
endogenous glucagon. This assumption is based on indirect
evidence in normal subjects infused with glucagon followed
by glucose (20). If this assumption were not valid, the values for MCR⊙ would be lower both in the
controls (9.5±0.4 ml/kg per min) and the uremics (3.6±0.4).
However, the significant differences between these groups (P < 0.001) would not be appreciably altered. On the other hand, if one assumes that
endogenous glucagon secretion is suppressed in controls
but not in uremics, the metabolic clearance rate in the
uremics remains significantly reduced when compared to
controls (P < 0.001).
The demonstration that hyperglucagonemia in uremia
is associated with decreased hormonal catabolism
strongly implicates the kidney as a principal site of
glucagon degradation. As noted above, the small portal-

TABLE I
Plasma Concentrations of Amino Acids during Intravenous Infusion of Glucagon (3 ng/kg body weight per min) in Normal and Uremic Subjects*

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>Condition</th>
<th>0</th>
<th>30 min</th>
<th>60 min</th>
<th>120 min</th>
<th>150-180 min†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taurine</td>
<td>N§</td>
<td>33±2</td>
<td>32±2</td>
<td>33±2</td>
<td>31±2</td>
<td>30±2</td>
</tr>
<tr>
<td></td>
<td>U‖</td>
<td>49±6</td>
<td>46±6</td>
<td>45±7</td>
<td>47±7</td>
<td>43±7</td>
</tr>
<tr>
<td>Threonine</td>
<td>N</td>
<td>109±6</td>
<td>111±7</td>
<td>110±7</td>
<td>109±8</td>
<td>104±7</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>132±14</td>
<td>132±17</td>
<td>117±16</td>
<td>114±16†</td>
<td>106±14**</td>
</tr>
<tr>
<td>Serine</td>
<td>N</td>
<td>101±4</td>
<td>101±4</td>
<td>101±5</td>
<td>99±5</td>
<td>94±5†</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>100±12</td>
<td>87±12</td>
<td>83±9</td>
<td>87±11†</td>
<td>80±14**</td>
</tr>
<tr>
<td>Prolin</td>
<td>N</td>
<td>158±16</td>
<td>161±15</td>
<td>158±15</td>
<td>155±16</td>
<td>146±14</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>285±11</td>
<td>282±15</td>
<td>264±16</td>
<td>261±16†</td>
<td>251±17†</td>
</tr>
<tr>
<td>Citrulline</td>
<td>N</td>
<td>29±5</td>
<td>29±4</td>
<td>29±5</td>
<td>26±4</td>
<td>23±2</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>86±11</td>
<td>84±13</td>
<td>83±13</td>
<td>83±13</td>
<td>78±10**</td>
</tr>
<tr>
<td>Glycine</td>
<td>N</td>
<td>207±16</td>
<td>209±17</td>
<td>210±17</td>
<td>207±16</td>
<td>204±16</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>399±65</td>
<td>386±72</td>
<td>353±61**</td>
<td>365±60†</td>
<td>336±59††</td>
</tr>
<tr>
<td>Alanine</td>
<td>N</td>
<td>295±22</td>
<td>307±31</td>
<td>307±29</td>
<td>306±27</td>
<td>294±22</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>309±25</td>
<td>295±31</td>
<td>280±23</td>
<td>270±24†</td>
<td>237±21††</td>
</tr>
<tr>
<td>a-Aminobutyrate</td>
<td>N</td>
<td>16±2</td>
<td>18±2</td>
<td>16±2</td>
<td>16±2</td>
<td>15±2</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>8±3</td>
<td>8±3</td>
<td>7±2</td>
<td>8±3</td>
<td>8±3</td>
</tr>
<tr>
<td>Valine</td>
<td>N</td>
<td>203±11</td>
<td>206±12</td>
<td>200±12</td>
<td>196±12</td>
<td>190±11</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>150±12</td>
<td>151±13</td>
<td>141±10</td>
<td>133±12†</td>
<td>127±13††</td>
</tr>
<tr>
<td>Cystine</td>
<td>N</td>
<td>99±12</td>
<td>94±19</td>
<td>91±16</td>
<td>87±14**</td>
<td>99±9</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>283±27</td>
<td>283±23</td>
<td>278±29</td>
<td>267±28</td>
<td>254±25</td>
</tr>
<tr>
<td>Methionine</td>
<td>N</td>
<td>28±1</td>
<td>27±2</td>
<td>28±2</td>
<td>29±1</td>
<td>30±1</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>26±3</td>
<td>25±3</td>
<td>22±2</td>
<td>20±2</td>
<td>19±3</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>N</td>
<td>60±3</td>
<td>59±4</td>
<td>58±3</td>
<td>54±5</td>
<td>55±4</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>56±5</td>
<td>59±6</td>
<td>53±6</td>
<td>50±7</td>
<td>44±6††</td>
</tr>
<tr>
<td>Leucine</td>
<td>N</td>
<td>112±7</td>
<td>111±8</td>
<td>109±8</td>
<td>105±10</td>
<td>106±9</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>90±9</td>
<td>87±9</td>
<td>81±7</td>
<td>78±8‡</td>
<td>75±10**</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>N</td>
<td>45±3</td>
<td>44±3</td>
<td>44±3</td>
<td>46±3</td>
<td>43±2</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>33±3</td>
<td>32±3</td>
<td>29±2</td>
<td>26±2‡</td>
<td>26±3**</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>N</td>
<td>49±3</td>
<td>48±3</td>
<td>48±3</td>
<td>48±3</td>
<td>46±2</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>55±5</td>
<td>56±6</td>
<td>50±5</td>
<td>47±4</td>
<td>44±5††</td>
</tr>
</tbody>
</table>

* Data presented as mean ± SE. P values refer to significance of difference from preinfusion values (paired t).
† Indicates that amino acids were measured at 150 min in uremics and 180 min in normal subjects.
§ Indicates normal subjects (n = 10).
‖ Indicates uremic subjects (n = 10).
¶ Indicates P < 0.05.
** Indicates P < 0.01.
†† Indicates P < 0.001.

728 Sherwin, Bastl, Finkelstein, Fisher, Black, Hendler, and Felig
Figure 7 Changes in plasma alanine in response to the infusion of glucagon in uremic and normal subjects. The normal subjects were studied during the infusion of glucagon at rates of 3 and 6 ng/kg per min. The infusion rate in the uremics was 3 ng/kg per min. The alanine response in dialyzed and undialyzed uremics was the same, consequently the data for the two uremic groups are combined in the figure. P values refer to the significance of the changes from the basal level. In the normal subjects (at both infusion rates) there were no significant changes in alanine levels during the infusion.

A peripheral gradient for glucagon (23, 24) is compatible with an extrahepatic degradative site. Glucagon degradative enzymes have, in fact, recently been demonstrated in kidney tissue (25). Consistent renal extraction of glucagon has been observed in the autotransplanted dog kidney (26). Recent studies in our laboratory reveal a fractional extraction ratio of glucagon across the kidney in the intact dog and rat of 40%. After the induction of renal failure by 75% nephrectomy, a consistent renal uptake of glucagon is no longer observed. Furthermore, renal artery clamping (27) and ureteral ligation (14) in dogs result in a rapid rise in plasma glucagon. In contrast, a decrease in circulating glucagon is observed after successful renal transplantation in man (28). These data thus indicate that renal function must be taken into account in interpreting plasma glucagon levels in a variety of pathological states. Hyperglycagonomia associated with traumatic shock (29), acute myocardial infarction (30), diabetic ketoacidosis (31), and hyperosmolar coma (32) may, in part, be explained by altered renal hemodynamics associated with these conditions.

Of particular interest were the effects of uremia and dialysis on the glycemic response to exogenous and endogenous glucagon. As compared to normal controls, undialyzed uremics demonstrated significantly increased glucose responses to physiological increments in plasma glucagon, induced by infusion of this hormone. In contrast, dialyzed uremics responded to exogenous glucagon in a manner comparable to controls (Fig. 5). Furthermore, when the glucagon infusion rate was increased in normals (6 ng/kg per min) so as to achieve increments in plasma glucagon comparable to the uremics, the glucose response remained two- to threefold greater in the undialyzed uremics (Fig. 6). In addition to the response to exogenous glucagon, the glycemic response to alanine-stimulated secretion of endogenous glucagon was also greater in undialyzed uremics than in controls or dialyzed uremics. These data thus suggest that uremia is characterized by increased sensitivity to the hyperglycemic effects of physiological increments in glucagon. This augmented sensitivity to glucagon returns to normal after dialysis.

The importance of altered tissue responsiveness to glucagon in uremia is underscored by the differential effects of dialysis on glucose tolerance and plasma glucagon levels. Although, in according with previous reports (5, 9–12), dialysis was associated with an improvement in glucose tolerance (Fig. 4), plasma glucagon levels remained unchanged. On the other hand, a direct linear correlation was observed between the 2-h plasma glucose response to glucose ingestion and the glycemic response to glucagon infusion. These observations suggest that increased tissue sensitivity to the glycemic effects of glucagon is an important factor in uremia-induced glucose intolerance. Improvement in glucose tolerance after chronic dialysis is associated with a return of glucagon sensitivity to normal. It should be noted that previous studies involving bolus injections of 0.15–1.0 mg of glucagon have shown a variable glucose response to glucagon in uremic patients (1, 2, 5, 33). However, the data on the BSDRs glucagon (less than 2 ng/kg per min in both the uremics and controls) indicate that such bolus injections represent pharmacological rather than physiological doses of glucagon.

Regarding the mechanism of augmented glucagon sensitivity in uremia, recent studies have demonstrated increased sensitivity to glucagon-induced hyperglycemia in circumstances of acute insulin deficiency (34) and in insulin-withdrawn diabetics (20). On the other hand, physiological increments in glucagon do not alter glucose tolerance in normal subjects, chemical diabetics, or in juvenile-onset diabetics receiving insulin (20). The current findings of hyperinsulinemia in the undialyzed uremics (Fig. 5) indicate that hypersensitivity to glucagon in uremia cannot be ascribed to insulin deficiency. The insulin response to oral glucose (Fig. 4),

---

intravenous alanine, and exogenous glucagon (Fig. 5) was increased in the undialyzed uremics, yet was associated with a deterioration in glucose tolerance, suggesting insulin resistance. Whether insulin resistance is a cause or a consequence of augmented tissue responsiveness to glucagon in undialyzed uremics remains to be determined. The current data do not exclude the possibility that uremia results in alterations in hepatic glucagon receptors or in steps subsequent to receptor binding, independent of altered tissue responsiveness to insulin.

Regarding amino acid concentrations in uremia, in accordance with previous observations (22, 35–37), uremic subjects demonstrated increases in plasma, glycine, cystine, citrulline, proline, and taurine, and decreases in tyrosine, valine, and α-amino butyrate. The amino acid pattern in uremia differed from prolonged starvation in which circumstance hypoalaninemia is a striking finding (38), thus it suggests that the alterations observed in uremia are not primarily the result of caloric deprivation. While increased glycine and proline levels are seen in protein malnutrition (39, 40), the threefold increases in citrulline and cystine in uremic subjects are not observed in protein deficiency (39, 40). Furthermore, dialyzed uremics were maintained on a diet of normal protein content (80 g). These data suggest that nondietary factors contribute to the changes observed in amino acids in uremia. The increased citrulline concentration may reflect alterations in urea cycle activity; elevated arginine levels have also been observed in uremic patients (22, 35–37). Particularly noteworthy are the normal levels of serine in the uremic group (Table I). Studies in normal subjects have shown that the kidney is the principal source of plasma serine which is extracted by the liver as well as muscle (41). The failure to observe a fall in serine in uremics suggests either a compensatory reduction in extrarenal uptake, stimulation of extrarenal production, or residual renal release in the uremic group.

Although the infusion of glucagon in the normal subjects failed to alter plasma amino acid levels, the uremics demonstrated reductions in virtually all amino acids (Table I). The glucagon-induced reduction in plasma alanine in the uremic patients exceeded that of all other amino acids. These results suggest increased sensitivity to the gluconeogenic effects of glucagon in uremia. Increased amino acid incorporation into glucose has been observed in perfused rat livers after nephrectomy (42). It should be noted that while dialysis normalized the glucagon response to glucagon (Fig. 5), the hypoalaninemic response to glucagon was comparable in dialyzed and nondialyzed patients. These observations suggest that the glycogenolytic and gluconeogenic responses to glucagon may be independently influenced by the uremic state.

ACKNOWLEDGMENTS

We thank William Sweet, Ralph Jacob, and Andrea Belous for their technical assistance and Tina Spinelli for her secretarial assistance. We are grateful to Kathi Hunt and the staff of the Clinical Research Center at Yale-New Haven Hospital for their efforts in caring for our patients. This work was supported in part by National Institutes of Health contract N01-AM-42221, and by National Institutes of Health grants AM 13526 and RR 125.

REFERENCES

Influence of Uremia and Hemodialysis on Glucagon.


